Related Experiment Videos
Chemotherapy in alveolar soft part sarcomas. What do we know?
P Reichardt1, T Lindner, D Pink
1Medizinische Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie, Robert-Rössle-Klinik, Helios-Klinikum Berlin, Universitätsklinikum Charité, Humboldt-Universität zu Berlin, Berlin, Germany. reichardt@rrk-berlin.de
European Journal of Cancer (Oxford, England : 1990)
|July 12, 2003
Summary
Alveolar soft part sarcoma (ASPS) rarely responds to chemotherapy, with over half of patients experiencing disease progression. Brain metastases are common, necessitating routine brain imaging for ASPS staging.
Area of Science:
- Oncology
- Rare Cancers
- Medical Research
Background:
- Alveolar soft part sarcoma (ASPS) is a rare malignancy with limited published data on treatment efficacy and outcomes.
- Chemotherapy response data for ASPS is inconclusive, highlighting a need for better understanding of treatment strategies.
Purpose of the Study:
- To evaluate the efficacy of palliative chemotherapy in Alveolar soft part sarcoma (ASPS).
- To determine the incidence and presentation patterns of brain metastases in ASPS patients.
- To provide evidence-based recommendations for ASPS management.
Main Methods:
- Retrospective analysis of an institutional sarcoma database and a comprehensive literature review.
- Inclusion of 8 ASPS patients from the institutional database and 60 from literature with chemotherapy data.
- Analysis of metastatic sites in 285 Stage IV ASPS patients.
Main Results:
- First-line chemotherapy showed limited efficacy: 4% complete remission, 3% partial remission, 41% stable disease, and 51% progressive disease.
- Brain metastases occurred in 30.5% of Stage IV ASPS patients, detected a median of 48 months post-diagnosis.
- Median survival after brain metastasis diagnosis was 12 months; median survival for Stage IV ASPS treated with chemotherapy was 36+ months.
Conclusions:
- ASPS exhibits a significantly higher incidence of brain metastases compared to other soft tissue sarcomas.
- Standard chemotherapy regimens for soft tissue sarcomas are largely ineffective against ASPS.
- Routine brain imaging is recommended for ASPS staging, and chemotherapy should be reserved for clinical trials, with a focus on developing targeted therapies.